收稿日期: 2020-02-05
网络出版日期: 2020-06-30
Calculation of the prevalence of progressive muscular atrophy among adults in China based on urban medical insurance data from 15 provinces
Received date: 2020-02-05
Online published: 2020-06-30
目的 分析进行性肌萎缩(progressive muscular atrophy,PMA)患者的基本人口学特征并测算其患病率。方法 研究基于我国15省2016年1月1日至12月31日的城镇职工和城镇居民医疗保险数据,排除18岁以下儿童。通过疾病诊断名称和疾病诊断编码来识别PMA患者,按照性别、地区和年龄进行亚组分析,并依据我国2010年全国人口普查数据计算PMA按年龄调整后的患病标化率,通过不估算诊断信息缺失的参保人群中潜在的PMA患者数和剔除诊断信息缺失率前10%的省份(湖北、山东)进行敏感性分析。结果 纳入的总参保人年数为99 609万,其中男性为51 841万,女性为47 767万。研究人群与我国2010年人口普查性别年龄结构类似,研究人群具有全国代表性。2016年我国PMA患病率为0.28/10万人年(95%CI:0.24~0.33),其中女性为0.21/10万人年(95%CI:0.16~0.26),男性为0.35/10万人年(95%CI:0.28~0.42)。我国PMA患病率存在地区差异,表现为西南地区患病率最低(0.11/10万人年,95%CI:0.07~0.15),西北地区患病率最高(3.47/10万人年,95%CI:0.80~7.99)。各年龄段患病率差异较小,其中70岁以上人群患病率相对较高。全国患病标化率为0.29/10万人年(95%CI:0.27~0.31)。不估算诊断信息缺失的参保人群中潜在的PMA患者数和剔除诊断信息缺失率前10%的省份后所得的敏感性分析结果分别为0.17/10万人年(95%CI:0.14~0.20)和0.24/10万人年(95%CI:0.20~0.28)。结论 通过测算我国城镇人口中成人PMA的患病率,为PMA相关医疗政策的制定提供基础数据,也为PMA疾病机制的研究提供线索。
许璐 , 陈璐 , 樊东升 , 冯菁楠 , 刘立立 , 詹思延 , 王胜锋 . 基于15省城镇医疗保险数据测算我国成人进行性肌萎缩患病率[J]. 北京大学学报（医学版）, 2020 , 52(3) : 521 -526 . DOI: 10.19723/j.issn.1671-167X.2020.03.019
Objective: To analyze the characteristics of patients with progressive muscular atrophy (PMA) and calculate the prevalence of PMA in China in 2016.Methods: A retrospective analysis based on China’s urban employee basic medical insurance data and the urban residence basic medical insu-rance data from January 1, 2016 to December 31, 2016 was carried out. Children under 18 years old were excluded. Patients with progressive muscular atrophy were identified by disease names and codes. Subgroup analyses by gender, region and age were carried out to calculate the gender-specific, region-specific and age-specific prevalences. Age-adjusted national prevalence was estimated based on 2010 Chinese census data. Sensitivity analyses were done by only considering the observed cases and by excluding the top 10% provinces regarding the missing rate of diagnostic information, respectively.Results: A total of 996.09 million person-years were included in this study, with 518.41 million person-years in males and 477.67 million person-years in females. The age and gender distribution of the study population was similar to that of the 2010 Chinese census data, therefore the study population was nationally representative. The prevalence of PMA in China in 2016 was 0.28 per 100 000 person-years (95%CI: 0.24-0.33), with 0.21 per 100 000 person-years (95%CI: 0.16-0.26) and 0.35 per 100 000 person-years (95%CI: 0.28-0.42) for females and males, respectively. Regional disparity existed in the Chinese PMA prevalence, with the lowest prevalence in Southwest region (0.11 per 100 000 person-years, 95%CI: 0.07-0.15) and the highest prevalence in Northwest region (3.47 per 100 000 person-years, 95%CI: 0.80-7.99). Age trend in the PMA prevalence was not obvious, but the prevalence among those aged 70 years and older was relatively higher. The age-adjusted prevalence based on 2010 Chinese census data was 0.29 per 100 000 person-years (95%CI: 0.27-0.31). The national prevalences calculated by only considering the observed cases and by excluding the top 10% provinces regar-ding the missing rate of diagnostic information were 0.17 per 100 000 person-years (95%CI: 0.14-0.20) and 0.24 per 100 000 person-years (95%CI: 0.20-0.28), respectively.Conclusion: This study is to calculate the prevalence of PMA among adults in urban China, which can provide basic statistics for the enactment of PMA related medical policies, and clues for the studies on the mechanisms of PMA.
Key words： Progressive muscular atrophy; Prevalence; Medical insurance
| [1] | Liewluck T, Saperstein DS. Progressive muscular atrophy[J]. Neurol Clin, 2015,33(4):761-773. |
| [2] | Fowler WS, Miller RD, Mulder DW, et al. Exertional dyspnea: a primary complaint in unusual cases of progressive muscular atrophy and amyotrophic lateral sclerosis[J]. Ann Intern Med, 1957,46(1):119-125. |
| [3] | Logroscino G, Piccininni M, Marin B, et al. Global, regional, and national burden of motor neuron diseases 1990—2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2018,17(12):1083-1097. |
| [4] | Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis[J]. J Neurol, 2020,267(4):944-953. |
| [5] | Pinho AC, Goncalves E. Are amyotrophic lateral sclerosis caregi-vers at higher risk for health problems?[J]. Acta Med Port, 2016,29(1):56-62. |
| [6] | Tsai CP, Wang KC, Hwang CS, et al. Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999—2008[J]. J Formos Med Assoc, 2015,114(7):612-619. |
| [7] | Riku Y, Atsuta N, Yoshida M, et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis[J]. BMJ Open, 2014,4(5):e005213. |
| [8] | Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS[J]. Neurology, 2009,73(20):1686-1692. |
| [9] | 王胜锋, 詹思延, 许璐, 等. 基于医保数据的单病种诊断信息快速结构化方法: 中国, CN109344250A [P]. 2019-02-15. |
| [10] | Xu L, Chen L, Wang S, et al. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study[J]. J Neurol Neurosurg Psychiatry, 2020,91(5):520-525. |
| [11] | Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis[J]. Lancet Glob Health, 2019,7(4):e448-e460. |
| [12] | Leigh PN, Ray-Chaudhuri K. Motor neuron disease[J]. J Neurol Neurosurg Psychiatry, 1994,57(8):886-896. |
| [13] | Chio A, Brignolio F, Leone M, et al. A survival analysis of 155 cases of progressive muscular atrophy[J]. Acta Neurol Scand, 1985,72(4):407-413. |
| [14] | Maragakis NJ. Motor neuron disease: progressive muscular atrophy in the ALS spectrum[J]. Nat Rev Neurol, 2010,6(4):187-188. |
| [15] | Marin B, Boumediene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis[J]. Int J Epidemiol, 2017,46(1):57-74. |
| [16] | 邢志宏, 叶植材. 中国统计年鉴 [M]. 北京: 中国统计出版社, 2017: 31. |
| [17] | Cui F, Liu M, Chen Y, et al. Epidemiological characteristics of motor neuron disease in Chinese patients[J]. Acta Neurol Scand, 2014,130(2):111-117. |
| [18] | Wicks P, Abrahams S, Leigh PN, et al. Absence of cognitive, behavioral, or emotional dysfunction in progressive muscular atrophy[J]. Neurology, 2006,67(9):1718-1719. |
| [19] | Chen L, Zhang B, Chen R, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China[J]. J Neurol Neurosurg Psychiatry, 2015,86(10):1075-1081. |
| [20] | Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, medicare supplemental insured, and medicaid enrolled populations: an administrative claims analysis[J]. BMC Musculoskelet Disord, 2012,13:103. |
| [21] | Ki M, Choi HY, Kim KA, et al. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study[J]. Liver Int, 2016,36(7):1067-1073. |
| [22] | Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009—2014[J]. JAMA, 2017,318(13):1241-1249. |
| [23] | Donnachie E, Schneider A, Mehring M, et al. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data[J]. Gut, 2018,67(6):1078-1086. |
/
| 〈 |
|
〉 |
